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Admission B-Type Natriuretic Peptide Levels and
In-Hospital Mortality in Acute Decompensated Heart Failure
Gregg C. Fonarow, MD, FACC,* William F. Peacock, MD,† Christopher O. Phillips, MD, MPH,‡
Michael M. Givertz, MD, FACC,§ Margarita Lopatin, MS, for the ADHERE Scientific Advisory
Committee and Investigators
Los Angeles and Mountain View, California; Cleveland, Ohio; and Boston, Massachusetts
Objectives This study was designed to determine whether admission B-type natriuretic peptide (BNP) levels are predictive of
in-hospital mortality in acute decompensated heart failure (HF).
Background Levels of BNP have been demonstrated to facilitate the diagnosis of HF and predict mortality in chronic sys-
tolic HF.
Methods B-type natriuretic peptide levels within 24 h of presentation were obtained in 48,629 (63%) of 77,467 hos-
pitalization episodes entered in ADHERE (Acute Decompensated Heart Failure National Registry). In-hospital
mortality was assessed by BNP quartiles in the entire cohort and in patients with reduced (n  19,544) as
well as preserved (n  18,164) left ventricular systolic function using chi-square and logistic regression
models.
Results Quartiles (Q) of BNP were Q1 (430), Q2 (430 to 839), Q3 (840 to 1,729), and Q4 (1,730 pg/ml). The BNP
levels were 100 pg/ml in 3.3% of the total cohort. Patients in Q1 versus Q4 were younger, more likely to be
women, and had lower creatinine and higher left ventricular ejection fraction. There was a near-linear relation-
ship between BNP quartiles and in-hospital mortality: Q1 (1.9%), Q2 (2.8%), Q3 (3.8%), and Q4 (6.0%), p 
0.0001. B-type natriuretic peptide quartile remained highly predictive of mortality even after adjustment for age,
gender, systolic blood pressure, blood urea nitrogen, creatinine, sodium, pulse, and dyspnea at rest, Q4 versus
Q1 (adjusted odds ratio 2.23 [95% confidence interval 1.91 to 2.62, p  0.0001]). The BNP quartiles indepen-
dently predicted mortality in patients with reduced and preserved systolic function.
Conclusions An elevated admission BNP level is a significant predictor of in-hospital mortality in acute decompensated
HF with either reduced or preserved systolic function, independent of other clinical and laboratory variables.
(Registry for Acute Decompensated Heart Failure Patients; http://www.clinicaltrials.gov/show/NCT00366639;
NCT00366639). (J Am Coll Cardiol 2007;49:1943–50) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.037p
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nvolved in volume homeostasis and cardiovascular remod-
ling. B-type natriuretic peptide (BNP) is a 32-amino-acid
eurohormone synthesized in ventricular myocardium
nd released into the circulation in response to ventricular
ilatation and pressure overload (1,2). B-type natriuretic
eptide is derived from an intracellular 108-amino-acid
recursor that is cleaved predominately into 2 fragments,
ielding a 76-amino-acid N-terminal fragment (NT-
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007, accepted February 5, 2007.roBNP) and BNP (1). Levels of BNP and NT-proBNP
ave been shown to be elevated in patients with left
entricular (LV) dysfunction and correlate with the New
ork Heart Association functional class (3). Clinical inves-
igations of natriuretic peptides have focused on the diag-
ostic usefulness for heart failure (HF) and LV dysfunction
nd their prognostic usefulness in chronic HF, acute coro-
ary syndromes, stable coronary artery disease, other med-
cal conditions, and community cohorts (3–11).
Whether plasma levels of BNP are predictive of in-
ospital mortality risk in patients hospitalized with acute
ecompensated HF has not been well studied. The prior
tudies that have examined the relationship between pre-
entation levels of BNP or NT-proBNP and short-term
ortality risk have been relatively small and not adequately
owered to assess in-hospital mortality independent of other
ariables (12–18). The primary aim of this study was to assess
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BNP and Mortality in Acute HF May 15, 2007:1943–50the relationship of BNP to in-
hospital mortality by using data
from ADHERE (Acute Decom-
pensated Heart Failure National
Registry). This registry collects de-
tailed hospitalization data from the
initial presentation at the hospital
or emergency department until
discharge, transfer, or in-hospital
death (19,20). Coming from a
large observational database, these
data reflect recent clinical charac-
teristics and in-hospital outcomes
for a broad cohort of patients hos-
pitalized with acute decompen-
sated HF (19–22).
ethods
ata used to determine risk associated with BNP levels
ere taken from ADHERE. This registry collects de-
ailed hospitalization data from initial presentation in the
ospital or emergency department until discharge, trans-
er, or in-hospital death (19,20). The ADHERE registry
ontains data on patients hospitalized with acute decom-
ensated HF in community, tertiary, and academic centers
rom all regions of the country (20). For the purpose of the
egistry, acute decompensated HF is defined as new-onset
ecompensated HF or decompensation of chronic, estab-
ished HF with symptoms sufficient to warrant hospitaliza-
ion. The design, methods, and patient characteristics in
DHERE have been described previously (19). Briefly,
edical records are reviewed at participating study sites, and
ata from consecutive eligible male and female patients18
ears of age at the time of hospitalization are entered in the
egistry using an electronic case report form incorporating
eal-time validity checking (19,20). These data include
emographic information, medical history, baseline clinical
haracteristics, initial evaluation, treatment received, proce-
ures performed, hospital course, and patient disposition.
tandardized definitions are used for all patient-related
ariables, clinical diagnoses, and hospital outcomes. Impor-
antly, registry participation does not require any alteration
f treatment or hospital care, and entry of data into the
egistry is not contingent on the use of any particular
herapeutic agent or treatment. Institutional review board
pproval is required for all participating centers; however,
nformed consent of individuals was not required for registry
ntry. To preserve patient confidentiality, direct patient
dentifiers are not collected, and data are reported only in
ggregate format. Therefore, registry entries reflect individ-
al hospitalization episodes, not individual patients, and
ultiple hospitalizations of the same patient may be entered
nto the registry as separate records.
In the beginning of 2003, ADHERE hospitals began
Abbreviations
and Acronyms
BMI  body mass index
BNP  B-type natriuretic
peptide
BUN  blood urea nitrogen
HF  heart failure
LV  left ventricular
LVEF  left ventricular
ejection fraction
NT-proBNP  N-terminal
pro-B-type natriuretic
peptide
Q  quartilemploying the expanded range BNP testing (range 0 to o,000 pg/ml). This current study analyzed ADHERE
ata from April 2003 through December 2004 (February
005 data transfer). During this time frame 191 of 229
DHERE hospitals reported having the capability of
ssessing BNP levels (176 BNP only, 15 BNP and NT-
roBNP, 14 NT-proBNP only, and 24 none). B-type
atriuretic peptide levels on presentation (first level obtained
ithin 24 h of presentation) were analyzed by the local
ospital laboratory and recorded in the medical record.
uring the analysis time frame, 48,629 (63%) of 77,467
atients episodes had BNP assessment. For the primary
nalyses, patients were grouped by BNP quartiles. Data
ere analyzed for the overall cohort as well as for those
atients with reduced (left ventricular ejection fraction
LVEF] 40%) and preserved (LVEF 40%) systolic
unction. Analysis of patients with LVEF 50% was also
erformed. Data were also assessed for each weight category
y body mass index (BMI) (kg/m2): underweight (BMI
18.5), healthy weight (BMI 18.5 to 24.9), overweight
BMI 25.0 to 29.9), and obese (BMI 30).
tatistical analyses. Data from ADHERE were used for
nalyses of clinical characteristics, treatments, and outcomes
or patient episodes of HF grouped by quartiles of BNP.
nalysis by BNP quartiles, continuous, and log-
ransformed BNP was performed. As log transformation
roduced similar findings, data are presented without log
ransformation for clarity. A relationship between mortality
nd BNP was examined using locally weighted smoother
egression scatterplots (loess). Procedure PLSMO from
misc S-PLUS library (F.E. Harrell, Department of Bio-
tatistics, Vanderbilt University, Nashville, Tennessee) was
sed to create the plot. The hypothesis of no differences in
atients’ characteristics and outcomes among 4 BNP quar-
iles was tested using chi-square, analysis of variance, and
ruskal-Wallis tests as appropriate. The Kruskal-Wallis
est was used to analyze outcome variables with skewed
istribution. Two-sided p values were reported. Because of
nticipated differences among the 4 BNP quartile groups in
edical history and clinical characteristics at presentation, it
as important to adjust the mortality comparison for
elevant prognostic factors. Of 80 demographic, medical
istory, and initial evaluation variables collected in AD-
ERE, classification and regression tree analysis and/or
ogistic regression models previously identified 8 variables as
he most important risk factors for in-hospital mortality
20,21,23). Mortality rates in the BNP quartiles were
ompared using logistic regression adjusted for these 8
ariables: age, blood urea nitrogen (BUN), systolic blood
ressure (SBP), diastolic blood pressure, creatinine, sodium,
eart rate, and dyspnea at rest, as well as gender. A total of
.2% of records were excluded for 1 or more missing values.
ultivariable analysis using 48 of 51 variables previously
escribed (21) resulted in little incremental improvement in
rognostic value. To adjust for multiple comparisons (e.g., 3),
nly p values0.017 were considered statistically significant
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May 15, 2007:1943–50 BNP and Mortality in Acute HFsing Bonferroni correction. With the large sample size,
tatistical significance with small differences in clinical
ariables was expected. Risk-adjusted mortality was also
ssessed separately in the cohort of patients with reduced
nd preserved LV systolic function (quantitative LVEF
ocumented in 75.5%). The relationship between risk-
djusted mortality and BNP was also analyzed with BNP as
continuous variable. There was little variation in BNP by
enter, hospital type, or region; thus, hierarchic analysis was
ot performed. The area under the receiver-operator curve
as used to assess the discrimination of the models. These
nalyses were performed using version 8.2 of SAS software
SAS Institute, Inc., Cary, North Carolina).
esults
rom April 2003 through December 2004, there were
8,629 (63%) of 77,467 patient episodes in 191 hospitals
hat had BNP assessment within 24 h of presentation. The
NP testing rate increased over time from 51.2% in
econd-quarter 2003 to 75.4% in fourth-quarter 2004 (p 
.0001). The distribution of BNP for these acute HF
ospitalizations is shown in Figure 1. B-type natriuretic
eptide levels were 100 pg/ml in 3.3% of the total cohort.
uartiles (Q) of BNP were Q1 (430 pg/ml), Q2 (430 to
39 pg/ml), Q3 (840 to 1,729 pg/ml), and Q4 (1,730
g/ml).
Patient characteristics as stratified by BNP quartiles are
hown in Table 1. Patients in BNP Q1 versus Q4 were
lightly younger (mean age 71.5 vs. 73.9 years) and were
ore likely to be women (55% vs. 49%). A greater propor-
ion of African Americans (22% vs. 16%) were in Q4 versus
1. Patients in Q1 versus Q4 were less likely to have a
istory of HF and coronary artery disease and were half as
ikely to have a history of chronic renal insufficiency, but
Figure 1 Distribution of BNP Values
Histogram of B-type natriuretic peptide (BNP)
values (pg/ml) among the 48,629 hospitalization episodes.hhese patients had a greater prevalence of a history of
iabetes (Table 1). Notably, there were few clinically rele-
ant differences observed in the admission signs and symp-
oms of HF by BNP quartile. Somewhat higher systolic
lood pressure and lower creatinine levels were associated
ith a lower BNP quartile. Patients in BNP Q4 were more
han twice as likely to have moderate to severe impairment
n LVEF (Q1 29% vs. Q4 70%).
In-hospital medication use by BNP quartiles is shown in
able 2. Most patients received intravenous diuretics (90%
o 94%), and there were only small differences by BNP
uartile. More than twice as many patients in BNP Q4
ersus Q1 were treated with inotropic agents or nesiritide,
hereas there was little difference in nitroglycerine use by
NP quartiles (Table 2). Use of beta-blockers and digoxin
uring hospitalization was modestly more frequent in pa-
ients in higher BNP quartiles. Use of ultrafiltration and
ialysis was significantly more frequent in higher BNP
uartile patients (Table 2).
The in-hospital mortality risk for the overall patient
opulation was 3.6% (1,760 of 48,629). There was a
ear-linear relationship between BNP and in-hospital
ortality: Q1 (1.9%), Q2 (2.8%), Q3 (3.8%), and Q4
6.0%), p  0.0001 (Fig. 2). For the 1,407 patients with
NP levels at or above 5,000 pg/ml, the in-hospital
ortality was 8.5%. B-type natriuretic peptide quartiles
ere highly predictive of mortality even after adjustment
or age, gender, SBP, BUN, creatinine, sodium, pulse,
nd dyspnea at rest, Q4 versus Q1, adjusted odds ratio
.23 (95% confidence interval 1.91 to 2.62), p  0.0001,
s shown in Table 3. The area under the receiver-
perator curve for the model was 0.77, indicating ade-
uate model discrimination (Table 3). Addition of up to
0 additional demographic, medical history, outpatient
edications, and initial assessment variables produced
imilar findings (area under the curve 0.79). As a contin-
ous variable, BNP was also predictive of mortality (Fig. 3). In
ultivariable analysis, for every 400-U increase in BNP, the
dds of risk-adjusted mortality were 9% higher (odds ratio
.09, 95% confidence interval 1.08 to 1.11, p  0.0001).
B-type natriuretic peptide quartiles also predicted mor-
ality in patients with LVEF 40%, LVEF 40%, and
VEF50% as shown in Figure 2. These findings for BNP
nd mortality were independent of other major risk factors
n patients with and without preserved systolic function.
hen the analysis was confined to patients with very low
VEF (15%, n  1,574) the median BNP was 1,539
g/ml, and higher BNP remained predictive of mortality
Q1, BNP 865 pg/ml, 1.5% vs. Q4, BNP 2,830 pg/ml,
.1%, p  0.0005). Of 38,242 hospitalizations with
ocumented BMI, there were 1,194 (3%) underweight,
2,018 (31%) healthy weight, 11,046 (29%) overweight,
nd 13,984 (37%) obese. There was a strong inverse
elationship between BMI and median BNP levels: un-
erweight 1,380 (interquartile range 732 to 2,890 pg/ml),
ealthy weight 1,217 (613 to 2,354), overweight 891 (480
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BNP and Mortality in Acute HF May 15, 2007:1943–50o 1,740), and obese 555 (294 to 1,103), p  0.0001. For
ach BMI category, except for the underweight group,
NP levels remained a significant univariate and multi-
ariate predictor of in-hospital mortality. B-type natri-
retic peptide levels were also independently predictive of
ortality in unique patients with new onset heart failure
n  11,707).
The BNP quartile groups also predicted other clinical
utcomes, including the need for mechanical ventilation,
ength of stay, time in the intensive care unit, and percent
ospitalization in the intensive care unit, as shown in
able 4. Patients in higher BNP quartiles were more
ikely to require mechanical ventilation and be hospital-
zed in the intensive care unit. These patients also had
atient Characteristic Stratified by BNP Quartile
Table 1 Patient Characteristic Stratified by BNP Quartile
Parameter
Q1
(n  1
Age (yrs, mean  SD) 71.5
Gender (% male) 4
Race (% black) 1
Medical history
History of heart failure (%) 7
Atrial fibrillation (%) 3
Coronary artery disease (%) 5
COPD/asthma (%) 3
Chronic renal insufficiency (%) 2
Chronic dialysis (%) 
Cardiac valvular disease (%) 1
Ventricular tachycardia/fibrillation (%)
Diabetes (%) 5
Hypertension (%) 7
Hyperlipidemia (%) 3
Current smoker (%) 1
Peripheral vascular disease (%) 1
Prior myocardial infarction (%) 2
Presentation variables
Dyspnea at rest (%) 3
Edema (%) 6
Fatigue (%) 2
Rales (%) 6
Systolic blood pressure (mm Hg, mean  SD) 145.5
Heart rate (beats/min, mean  SD) 87
Body mass index (kg/m2, mean  SD) (n  38,242) 32.8
Blood urea nitrogen (mg/dl, median, 25th, 75th) 2
15.0
Creatinine (mg/dl, median, 25th, 75th)
0.9
Sodium (mmol/l, mean  SD) 138.2
Elevated troponin (%) (n  42,636)
QRS duration (ms, mean  SD) (n  43,463) 107.6
LVEF (median) (n  37,708) 5
LVEF 40% or moderate/severe impairment (%) (n  41,846) 2
Congestion on first chest X-ray (%) (n  45,659) 6
ll p  0.0001 except hyperlipidemia, heart rate (p  0.01), and hypertension (p  0.09). Kruska
BNP  B-type natriuretic peptide; COPD  chronic obstructive pulmonary disease; LVEF  leftonger length of stays. Patients with higher BNP levels an admission were also less likely to be asymptomatic at
ospital discharge.
iscussion
he ADHERE provides insights into the relationship
mong presenting characteristics, laboratories, and in-
ospital outcomes in a broad population of patients recently
ospitalized with acute decompensated HF. This analysis of
48,000 acute decompensated HF hospitalizations, in pa-
ients demographically and clinically similar to those seen in
ther large community- or Medicare-based evaluations
19,22), demonstrates that the risk of in-hospital mortality
an be reliably estimated using BNP obtained on hospital
BNP Quartile
)
Q2 430–839
(n  12,146)
Q3 840–1,729
(n  12,156)
Q4 >1,730
(n  12,166)
0 73.9 13.7 74.1 13.7 73.9 13.7
47 49 51
16 18 22
73 77 82
36 32 28
59 62 63
34 31 30
26 32 45
1 3 10
23 24 25
8 10 12
44 41 40
76 75 75
39 39 37
13 14 16
19 20 22
29 33 35
34 35 35
66 66 65
29 30 31
69 71 72
2 145.4 32.3 142.9 33.3 141.2 33.8
88 23 88 22 87 21
29.6 7.5 27.7 6.7 26.0 6.0
24.0 27.0 33.0
17.0, 36.0 19.0, 40.3 22.0, 50.0
1.3 1.4 1.7
1.0, 1.7 1.1, 1.9 1.2, 2.5
138.1 4.6 137.8 4.7 137.6 4.9
4 6 9
5 114.1 33.9 118.8 35.1 121.0 35.4
40 35 28
42 57 70
75 78 79
s test used for blood urea nitrogen and creatinine.
lar ejection fraction; Q  quartile.<430
2,161
 14.
5
6
1
4
2
7
0
1
9
6
0
6
9
3
6
4
0
8
9
3
 31.
 21
 8.8
2.0
, 32.0
1.2
, 1.5
 4.4
3
 31.
0
9
8dmission. Overall, in-hospital mortality was 3.6%, but this
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May 15, 2007:1943–50 BNP and Mortality in Acute HFortality risk varied more than 3- to 4-fold on the basis of
he patient’s initial BNP. B-type natriuretic peptide pro-
ides risk prediction independently of numerous other
linical and laboratory variables previously demonstrated to
e predictive of in-hospital outcomes. This relationship
etween BNP and outcome persisted in hospitalized HF
atients with both reduced and preserved systolic function
nd across BMI categories. Our findings confirm that BNP
rovides prognostic information among patients with car-
iovascular disease, but they are the first to demonstrate this
elationship with in-hospital mortality among patients hos-
italized with acute decompensated HF.
Natriuretic peptides have been shown to predict progno-
is in patients with acute coronary syndromes, stable coro-
ary artery disease, chronic HF, and a variety of other
edical conditions, as well as in community cohorts (6–11).
here have been relatively few studies assessing the role of
atriuretic peptide testing for predicting prognosis in pa-
ients presenting with acute decompensated HF. Harrison
t al. (24) found that BNP levels measured in 325 patients
resenting to the emergency department with dyspnea were
redictive of cardiac events (cardiac death, emergency de-
artment visit, or admission for a cardiac cause) over the
nsuing 6 months. The REDHOT (Rapid Emergency
epartment Heart Failure Outpatient Trial) was a 10-
enter study assessing the relationship between BNP levels
nd 90-day outcomes of patients presenting to the emer-
ency department with shortness of breath (13). The BNP
evels upon presentation were predictive of 90-day mortality
Inpatient Medications and Procedures Stratified
Table 2 Inpatient Medications and Procedu
Parameter
Q1 <
(n  12
Intravenous medications during hospitalization
Diuretics (%) 9
Inotropes (%)
Vasodilator (%) 1
Nesiritide (%) 1
Nitroglycerin (%)
Nitroprusside (%) 
Oral medications during hospitalization
ACE inhibitors (%) 5
ARB (%) 1
Beta-blocker (%) 6
Calcium channel blocker (%) 2
Digoxin (%) 2
Diuretics (%) 7
Peripheral vasodilator (%)
Warfarin (%) 3
Procedures during hospitalization
Cardiac catheterization (%) 1
Dialysis (%)
Ultrafiltration (%) 
All p  0.0001, except nitroprusside (p  0.06).
ACE  angiotensin-converting enzyme; ARB  angiotensin receptorates, but multivariable analysis included only New York ceart Association functional class and disposition. In an-
ther analysis of 96 patients hospitalized with acute HF,
dmission NT-proBNP levels were not predictive of subse-
uent events (16). A larger report compared differences in
T-proBNP levels among 1,256 patients with and without
cute HF and the relationship between NT-proBNP levels
nd HF symptoms in a pooled analysis of 3 studies and 1
egistry cohort (18). The investigators found that in the
cute HF subgroup, a presenting NT-proBNP concentra-
ion 5,180 pg/ml was predictive of death by 76 days.
inally, in a recent analysis of the PRIDE (ProBNP
nvestigation of Dyspnea in the Emergency Department)
tudy of 599 patients who presented to the emergency
epartment with dyspnea, it was observed that an elevated
T-proBNP concentration at presentation was predictive
f death by 1 year after presentation, independent of other
rognostic variables (17). These prior studies have mostly
nvolved a mixed population of patients presenting with
yspnea, including patients not ultimately diagnosed as
aving heart failure; have involved relatively few study sites;
ave been inadequately powered; and as a result they have
ot adequately investigated whether natriuretic peptides are
redictive of in-hospital mortality risk.
Because multiple risk factors can exist in the same patient,
o be meaningful, analysis of the predictive value of a
otential biomarker must consider its relationship to other
rognostic factors and predictive models (20). As higher
NP levels are associated with other clinical presentation
nd laboratory variables that are indicative of higher risk, it
NP Quartile
tratified by BNP Quartile
BNP Quartile
Q2 430–839
(n  12,146)
Q3 840–1,729
(n  12,156)
Q4 >1,730
(n  12,166)
94 94 90
8 12 15
23 30 34
17 23 28
8 9 8
1 1 1
57 58 55
16 15 13
69 72 74
27 22 20
34 35 34
79 78 75
7 8 10
31 27 24
9 9 7
2 4 12
1 2 5
r; BNP  B-type natriuretic peptide.by B
res S
430
,161)
0
6
7
1
6
1
4
7
1
9
9
6
5
0
0
1
1ould be speculated that BNP levels, although providing
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BNP and Mortality in Acute HF May 15, 2007:1943–50rognostic information in isolation, do not provide mean-
ngful incremental risk prediction beyond traditional assess-
ent. In this study, patients in the higher BNP quartiles
ere slightly older, and had a higher BUN, a lower
dmission SBP, and a lower LVEF than those in lower
NP quartiles. However, even after adjustment for multiple
ther prognostic factors previously identified by classifica-
ion and regression tree analysis and/or logistic regression
odels as the most important risk factors for in-hospital
ortality in acute decompensated HF and stratification for
V systolic function, the relationship between BNP and
ortality persisted. This study demonstrates that assess-
ent of admission BNP levels can provide prognostic
nformation regarding in-hospital mortality in a broad
opulation hospitalized with HF, which is incremental to
linical assessment and prior risk prediction models.
National guidelines for acute coronary syndromes recom-
end the use of the biomarkers cardiac troponin and BNP
or prognosis and risk stratification (25). Current HF
uidelines, however, recommend consideration of BNP
Figure 2 Relationship Between BNP Quartiles and In-Hospital M
In-hospital mortality rates by B-type natriuretic peptide (BNP) quartiles (Q) (unadjus
(LVEF) 40% (n  19,544) (B), in patients with LVEF 40% (n  18,164) (C), and inesting solely for diagnostic purposes, and only in patients rhere the initial diagnosis is uncertain (26). These new
ndings suggest that assessment of presentation BNP levels
n patients hospitalized with HF provides independent
rognostic information regarding in-hospital mortality and
ther clinical outcomes and may be useful to stratify risk in
F patients. In light of the value of BNP and NT-proBNP
esting in providing short-term and long-term prognostic
nformation in patients presenting with acute decompen-
ated HF, routine assessment of BNP or NT-proBNP levels
ay be considered (17,18). Unlike LVEF, which is fre-
uently not available to clinicians for hours to days after
ospital admission, BNP levels are generally available
ithin 15 min to a few hours of presentation and are
redictive of subsequent outcome in patients with both
educed and preserved systolic function. This incremental
rognostic information provided by BNP has the potential
o aid in medical decision making. Patients judged to be at
igher risk may receive higher level monitoring and earlier,
ore intensive treatment for acute decompensated HF.
onversely, patients estimated to be at lower risk may
lity
the entire patient cohort (A), in patients with left ventricular ejection fraction
nts with LVEF 50% (n  12,631) (D). Each among-group comparison p  0.0001.orta
ted) in
patieeceive lower level monitoring and be managed less inten-
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May 15, 2007:1943–50 BNP and Mortality in Acute HFively. However, prospective studies will be necessary to
alidate this hypothesis.
tudy limitations. Potential limitations of the current
nalysis must be acknowledged. Real-world practice infor-
ation can be both an advantage and a disadvantage of
nalyses based on registry data. This real-world study used
esults of various commercially available BNP assays rather
han results from a single central core laboratory. Although
his methodology may introduce great variability to BNP
esting results, this approach makes these findings more
pplicable to clinical practice. It should also be noted that to
he extent that different commercially available BNP assays
roduce results that vary, the specific BNP level cutpoints
or risk stratification may vary. These study results can be
nfluenced by differences in disease assessment, back-
round medical therapy for heart failure, in-hospital
reatments, and documentation patterns at participating
nstitutions. However, ADHERE reflects patients cared
or by thousands of clinicians at hundreds of hospitals
cross the country, thus providing an excellent opportu-
ity to adjust for this variation and determine the added
isk prediction provided by BNP (20). Conversely, it
ust be considered that these findings may not apply to
djusted and Unadjustedn-Hospital Mortality Risk by BNP Quartile
Table 3 Adjusted and UnadjustedIn-Hospital Mortality Risk by BNP Quartile
Category
BNP Quartile Comparisons
Q2 vs. Q1 Q3 vs. Q1 Q4 vs. Q1
Unadjusted* 1.50 (1.27–1.79) 2.11 (1.80–2.48) 3.41 (2.93–3.97)
p  0.0001 p  0.0001 p  0.0001
Adjusted† 1.40 (1.18–1.66) 1.94 (1.65–2.29) 3.17 (2.72–3.69)
p  0.0001 p  0.0001 p  0.0001
Adjusted‡ 1.33 (1.12–1.58) 1.65 (1.40–1.94) 2.34 (2.00–2.74)
p  0.0015 p  0.0001 p  0.0001
Adjusted§ 1.46 (1.19–1.78) 1.84 (1.51–2.23) 2.74 (2.26–3.31)
p  0.0003 p  0.0001 p  0.0001
Adjusted 1.28 (1.08–1.53) 1.58 (1.34–1.86) 2.23 (1.91–2.62)
p  0.0057 p  0.0001 p  0.0001
dds ratios, (95% confidence intervals), p values. No Bonferroni adjustment applied. *Area under
he receiver-operator characteristic curve (AUC) 0.62. †Age, gender. (AUC 0.66). ‡Age, gender,
lood urea nitrogen (BUN), systolic blood pressure (BP), creatinine. (AUC  0.75). §Age, gender,
UN, systolic BP, creatinine, left ventricular ejection fraction0.40 ormoderate/severe. (AUC 0.75).
Age, gender, BUN, systolic BP, creatinine, sodium, pulse, dyspnea at rest. (AUC  0.77).
atient Outcomes Stratified by BNP Levels
Table 4 Patient Outcomes Stratified by BNP Levels
Parameter
Q1 <430
(n  12,161)
In-hospital mortality (%) 1.9
Mechanical ventilation (%) 3.1
Cardiopulmonary resuscitation (%) 0.6
ICU admission (%) 12.8
Length of stay, mean, median, 25th, 75th (days) 5.2
4.0, 2.7, 6.2
Asymptomatic at hospital discharge (%) 48.8ll p values by analysis of variance, except by Kruskal-Wallis test where indicated by *.
BNP  B-type natriuretic peptide; ICU  intensive care unit.atients who are cared for in settings that deviate
ubstantially from those in ADHERE.
Other factors to consider include that each patient’s
ctual risk may be influenced by many factors not measured
r considered in this analysis. It thus must be emphasized
hat BNP levels, use of other predictive variables, and
pplication of risk prediction models enhance, but are not
ntended to replace, physician assessment. Because the
DHERE registry does not contain specific patient iden-
ifiers, information regarding patient status following hos-
ital discharge is not available. Thus, the effects of BNP on
fter-discharge mortality risks cannot be determined in this
tudy. Similarly, because of the lack of patient identifiers,
he analyzed cohorts may contain multiple admissions for
he same patient. This should not have influenced the study
esults, as the principal outcome parameter, in-hospital
ortality as it relates to the admission BNP level, is specific
o individual hospitalization episodes and analysis confined
o unique new-onset heart failure patients in this study
ielded similar findings (20). Despite these potential limi-
Figure 3 Scatterplot Smoother of BNP
Levels and In-Hospital Mortality
Local regression scatterplot smoother (loess) of B-type natriuretic peptide
(BNP) levels and in-hospital mortality risk. The vertical marks on the loess line
indicate density of the data.
BNP Quartile
p Value
30–839
12,146)
Q3 840–1,729
(n  12,156)
Q4 >1,730
(n  12,166)
2.8 3.8 6.0 0.0001
3.7 3.9 4.1 .0002
0.9 1.2 1.7 0.0001
15.4 16.6 19.6 0.0001
5.7
2.9, 7.0
5.9
4.5, 3.0, 7.1
6.3
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0.0001
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BNP and Mortality in Acute HF May 15, 2007:1943–50ations, the current analysis of the ADHERE registry
epresents the largest analysis to date of the predictive
apability of a biomarker in patients hospitalized with
ardiovascular disease.
onclusions
n elevated admission BNP level is a significant indepen-
ent predictor of in-hospital mortality in acute HF. B-type
atriuretic peptide level is predictive of in-hospital mortality
n patients with either reduced or preserved LVEF inde-
endent of other clinical and laboratory variables. In light of
he demonstration of incremental prognostic information,
he BNP assay may be considered for inclusion as part of the
ssessment of patients presenting with acute decompensated
F. Further research will be necessary to determine
hether patients with higher admission BNP will benefit
rom more intensive monitoring and aggressive treatment
trategies.
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